Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.36 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225485 | 1.00 | BACE1 (0.40) | BACE1CYP26A1CYP26B1NR1H4TGM2 | |
| SCHEMBL4485308 | 0.92 | LTA4H (0.39) | BACE1CYP26A1CYP26B1NR1H4TGM2 | |
| SCHEMBL4485313 | 0.92 | LTA4H (0.39) | BACE1CYP26A1CYP26B1NR1H4TGM2 | |
| SCHEMBL226931 | 0.92 | BACE1 (0.40) | BACE1TGM2MEN1KMT2AMAPK1 | |
| SCHEMBL225644 | 0.92 | BACE1 (0.40) | BACE1TGM2MCHR1NAMPTLSS | |
| SCHEMBL226595 | 0.92 | BACE1 (0.40) | BACE1TGM2MEN1KMT2AMAPK1 | |
| SCHEMBL226593 | 0.92 | BACE1 (0.40) | BACE1TGM2MEN1KMT2AMAPK1 | |
| SCHEMBL226930 | 0.92 | BACE1 (0.40) | BACE1TGM2MEN1KMT2AMAPK1 | |
| SCHEMBL225643 | 0.92 | BACE1 (0.40) | BACE1TGM2MCHR1NAMPTLSS | |
| SCHEMBL4504439 | 0.91 | NR1H4 (0.38) | BACE1CYP26A1CYP26B1NR1H4TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128409-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20120004202-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-7858616-B2 | Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-7547703-B2 | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-06-16 | — | — | US | disclosed |
| EP-1835907-B1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1835907-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-7169936-B2 | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ROTH GERALD J | 2007-01-04 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20060148883-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006067175-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148883-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | COL1A1, MMP1, FOXM1 | BACE1 2383/4885CYP26A1 154/4885CYP26B1 236/4885 |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, EGFR | BACE1 2157/4885CYP26A1 1711/4885CYP26B1 2038/4885 |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | BACE1 1615/4885CYP26A1 517/4885CYP26B1 494/4885 |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | KDR, FLT1, EGFR | BACE1 2157/4885CYP26A1 1711/4885CYP26B1 2038/4885 |
| US-20140128409-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | COL1A1, MMP1, FOXM1 | BACE1 2383/4885CYP26A1 154/4885CYP26B1 236/4885 |
| US-20120004202-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | COL1A1, MMP1, FOXM1 | BACE1 2383/4885CYP26A1 154/4885CYP26B1 236/4885 |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, ERBB2 | BACE1 2291/4885CYP26A1 1177/4885CYP26B1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.